Ishita Drugs & Industries Ltd
NSE: BSE: 524400
₹76.54
(-4.86%)
Fri, 13 Mar 2026, 04:10 am
Market Cap240.57M
PE Ratio25.74
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KIshita Drugs & Industries Analysis
dividend
- Unable to evaluate Ishita Drugs & Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Ishita Drugs & Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Ishita Drugs & Industries is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Ishita Drugs & Industries is profitable, therefore cash runway is not a concern.
- Ishita Drugs & Industries is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (485.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 52.2x debt.
- Ishita Drugs & Industries's cash and other short term assets cover its long term commitments.
- Ishita Drugs & Industries earns more interest than it pays, coverage of interest payments is not a concern.
- Ishita Drugs & Industries's level of debt (2.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (2.2% vs 2.4% today).
- High level of physical assets or inventory.
management
- The average tenure for the Ishita Drugs & Industries board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Jagdish's remuneration is about average for companies of similar size in India.
- Jagdish's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Ishita Drugs & Industries is not covered by any analysts.
past
- Ishita Drugs & Industries's 1-year earnings growth exceeds its 5-year average (62.2% vs 22.2%)
- Ishita Drugs & Industries has delivered over 20% year on year earnings growth in the past 5 years.
- Ishita Drugs & Industries has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Ishita Drugs & Industries's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (62.2% vs 22.7%).
- Ishita Drugs & Industries used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Ishita Drugs & Industries has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Ishita Drugs & Industries's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Ishita Drugs & Industries's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Ishita Drugs & Industries is good value based on assets compared to the IN Pharmaceuticals industry average.
- Ishita Drugs & Industries is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Ishita Drugs & Industries is good value based on earnings compared to the India market.
- 524400 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524400 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524400 is down -4.7% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524400 is down -4.7% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800